Previous 10 | Next 10 |
Qualigen Therapeutics (NASDAQ:QLGN -1.6%) said on Tuesday it had begun IND-enabling studies for its lead program, QN-302, to treat pancreatic cancer, and potentially prostate cancer and other solid tumors. The company said its Investigational New Drug, or IND-enabling...
A P otential T reatment for Pancreatic Cancer in A ddition to O ther T umors of H igh U nmet C linical N eed CARLSBAD, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLG...
Qualigen Therapeutics (NASDAQ:QLGN) stock rose June 2 after the company said it completed the acquisition of a majority stake in Israeli diagnostics company NanoSynex. Qualigen said NanoSynex's technology is an Antimicrobial Susceptibility Testing (AST) platform that aims to provide accu...
Transaction expected to significantly advance commercial readiness of Nano S ynex’ s innovative diagnostic s technology platform focused on the $30+ Billion global infectious disease testing market Compan...
Abstracts Highlight In Vitro and In Vivo Activity of Qualigen’s Pan-RAS inhibitor in (1) Pancreatic Cancer, and (2) Malignant Peripheral Nerve Sheath Tumors CARLSBAD, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life scien...
CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today annou...
Qualigen Therapeutics press release (NASDAQ:QLGN): Q1 GAAP EPS of -$0.12 beats by $0.07. Revenue of $0.72M (-62.1% Y/Y) misses by $0.14M. As of March 31, 2022, Qualigen Therapeutics had $13.6 million in cash For further details see: Qualigen Therapeutics GAAP EPS of -$0.12 beats by $0.0...
CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today annou...
Innovative Technology Aims to Accelerate Antimicrobial Susceptibility Test Result Times by Six-Fold CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
Qualigen Therapeutics (NASDAQ:QLGN) is acquiring a majority stake in bacterial infection-focused Israeli diagnostics company NanoSynex. Qualigen’s purchase of the controlling interest in NanoSynex will mainly consist of a stock-for-stock acquisition with a controlling shareholder ...
News, Short Squeeze, Breakout and More Instantly...
Qualigen Therapeutics Inc. Company Name:
QLGN Stock Symbol:
NASDAQ Market:
Qualigen Therapeutics Inc. Website:
A look at the top 10 most actives in the United States American Rebel Holdings Inc. (AREB) rose 60.3% to $0.83355 on volume of 56,112,820 shares DatChat Inc. (DATS) rose 71.2% to $1.78 on volume of 33,845,116 shares Autonomix Medical Inc. (AMIX) rose 97.4% to $1.22 on volume of 33,054,234...
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...